Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$42.18 USD

42.18
890,330

+1.07 (2.60%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $42.20 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.

West Pharmaceutical (WST) Q1 Earnings Top Estimates, Revenues Lag

West Pharmaceutical's (WST) first-quarter earnings reflect strength in the Proprietary Products segment and operating margin expansion.

Align Technology (ALGN) Q1 Earnings Lag Estimates, Margins Fall

Robust Clear Aligner case volume growth and increased uptake of the iTero Element 5D Plus are driving Align Technology's (ALGN) first-quarter top line.

Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Down

Impressive performance by the Home Health and Hospice segments drove Amedisys' (AMED) revenues in the first quarter.

Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates

Abiomed's (ABMD) strength in Impella product revenues drives its Q4 top line.

Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 12.68% and 6.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ecolab's (ECL) Q1 Earnings in Line, Revenues Beat Estimates

Ecolab's (ECL) robust performance across all of its segments drives its Q1 sales despite business challenges.

Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?

Quidel's (QDEL) first-quarter results are likely to reflect continued strength across its SARS-related products.

Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

QGEN or ILMN: Which Is the Better Value Stock Right Now?

QGEN vs. ILMN: Which Stock Is the Better Value Option?

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors are optimistic about QIAGEN's (QGEN) recent expansion in test menu and strategic collaborations.

QIAGEN (QGEN) QuantiFeron Hits New Sales Landmark in TB Testing

According to QIAGEN (QGEN), QuantiFERON is different from other IGRA tests based on its efficient workflow.

Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock?

Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Illumina (ILMN) Debuts TSO Comprehensive Test in Europe

Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.

Illumina (ILMN) Invests in Seven Additional Genomics Startups

Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.

Why Is Qiagen (QGEN) Down 11.3% Since Last Earnings Report?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is QIAGEN (QGEN) a Great Stock for Value Investors?

Is QIAGEN (QGEN) a great pick from the value investor's perspective right now? Read on to know more.

QIAGEN (QGEN) Q4 Earnings Surpass Estimates, Margins Down

High demand for COVID-19 test products and improving trends in the non-COVID portfolio drove QIAGEN's (QGEN) fourth-quarter revenues.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors continue to be optimistic about QIAGEN's (QGEN) progress with testing solutions and strategic collaborations.

QIAGEN (QGEN) to Boost Testing Capacity With Liquid-Based Kit

QIAGEN's (QGEN) artus SARS-CoV-2 Prep&Amp UM is faster than standard processes and can spot the virus more reliably, including the new Omicron variant.

The Zacks Analyst Blog Highlights: Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics and Quidel Corp.

Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics,and Quidel Corp. are highlighted in this analyst blog.

Riya Anand headshot

3 Diagnostics Stocks in Focus Amid the Omicron Outbreak

Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.

QIAGEN (QGEN), Denovo to Develop CDx Test for Lymphoid Cancer

QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors are optimistic about QIAGEN (QGEN) on strong third-quarter results and raised 2021 guidance.

QIAGEN (QGEN) Gets CE Mark for QuantiFERON SARS-CoV-2 Assay

QIAGEN's (QGEN) QuantiFERON SARS-CoV-2 assay enables a comprehensive assessment of immunity developed by COVID-19 vaccines.